Literature DB >> 8153401

Antimalarial agents and lupus.

D J Wallace1.   

Abstract

Antimalarials are under-utilized, disease-modifying agents that are useful in the management of lupus erythematosus. Antimalarials can promote a remission in non-organ-threatening lupus and decrease its risk of dissemination. They are especially useful for cutaneous and inflammatory joint disease and have modest actions in improving serositis, fatigue, and cognitive dysfunction. As agents that do not depress the bone marrow or promote opportunistic infections, antimalarials have potential applications in combination with other antilupus medications and with each other.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8153401

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  17 in total

Review 1.  Recognition and management of systemic lupus erythematosus.

Authors:  J O Schroeder; H H Euler
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  Seizure associated with chloroquine therapy in a patient with systemic lupus erythematosus.

Authors:  Antonio G Tristano; Luz Falcón; María Willson; Ivette Montes de Oca
Journal:  Rheumatol Int       Date:  2004-01-23       Impact factor: 2.631

3.  Antimalarials may influence the risk of malignancy in systemic lupus erythematosus.

Authors:  G Ruiz-Irastorza; A Ugarte; M V Egurbide; M Garmendia; J I Pijoan; A Martinez-Berriotxoa; C Aguirre
Journal:  Ann Rheum Dis       Date:  2007-01-04       Impact factor: 19.103

4.  Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease.

Authors:  Michael D Geschwind; Amy L Kuo; Katherine S Wong; Aissa Haman; Gillian Devereux; Benjamin J Raudabaugh; David Y Johnson; Charles C Torres-Chae; Ron Finley; Paul Garcia; Julie N Thai; Hugo Q Cheng; John M Neuhaus; Sven A Forner; Jacque L Duncan; Katherine L Possin; Stephen J Dearmond; Stanley B Prusiner; Bruce L Miller
Journal:  Neurology       Date:  2013-10-11       Impact factor: 9.910

5.  Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.

Authors:  J Demarchi; S Papasidero; M A Medina; D Klajn; R Chaparro Del Moral; O Rillo; V Martiré; G Crespo; A Secco; A Catalan Pellet; C Amitrano; C Crow; C Asnal; P Pucci; F Caeiro; N Benzanquen; J P Pirola; M Mayer; F Zazzetti; S Velez; J Barreira; N Tamborenea; L Santiago; L Raiti
Journal:  Clin Rheumatol       Date:  2017-09-14       Impact factor: 2.980

6.  Polymorphism of the beta3-adrenergic receptor and lipid profile in patients with rheumatoid arthritis and systemic lupus erythematosus treated with chloroquine.

Authors:  J F Muñoz-Valle; M Vázquez-Del Mercado; S Ruiz-Quezada; E Oregón-Romero; R E Navarro-Hernández; J Ramírez-Barragán; G Martínez-Bonilla; G Bernard-Medina; B E Bastidas-Ramírez; B Ruiz-Madrigal; A Panduro
Journal:  Rheumatol Int       Date:  2003-03-12       Impact factor: 2.631

Review 7.  Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop?

Authors:  Sinthiya Punnialingam; Munther A Khamashta
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

8.  Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays.

Authors:  Mohamed A Kamal; William J Jusko
Journal:  J Clin Pharmacol       Date:  2004-09       Impact factor: 3.126

9.  The -844 G/A PAI-1 polymorphism is associated with mRNA expression in rheumatoid arthritis.

Authors:  Nora Magdalena Torres-Carrillo; Norma Torres-Carrillo; Mónica Vázquez-Del Mercado; Vidal Delgado-Rizo; Edith Oregón-Romero; Isela Parra-Rojas; José Francisco Muñoz-Valle
Journal:  Rheumatol Int       Date:  2007-09-26       Impact factor: 2.631

10.  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort.

Authors:  Guillermo J Pons-Estel; Luis A González; Jie Zhang; Paula I Burgos; John D Reveille; Luis M Vilá; Graciela S Alarcón
Journal:  Rheumatology (Oxford)       Date:  2009-05-19       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.